Chronic Lymphocytic Leukemia
December 2017 Issue
 
 
 

Nearly every major medical breakthrough over the past 50 years can be attributed to new discoveries that were made possible through meticulous biomedical research. Many diseases and conditions that previously took a heavy toll on patients in terms of both morbidity and mortality are now either treatable or preventable thanks in large part to painstaking research that expanded the frontiers of scientific knowledge and moved the most promising basic research developments into tangible health benefits through human clinical trails. Ongoing research is also the key that will open the door to additional major medical advances and breakthroughs in the future.

Our staff at Medifocus is committed to keeping our subscribers to the Medifocus Digest Alert on Chronic Lymphocytic Leukemia abreast of the latest new research developments that have recently been published in the medical literature for this condition. In this issue of the Digest Alert, you will find a focused list of hand-picked journal article references that represent the latest advances in basic and clinical research for Chronic Lymphocytic Leukemia. These articles represent the current state-of-the-art of the research that will hopefully lead to additional major advances and breakthroughs in the clinical management of Chronic Lymphocytic Leukemia. You can access the summaries of each article referenced below by simply clicking on the article Title.

We will continue to update you with the latest scientific and clinical developments through the Medifocus Digest Alert on Chronic Lymphocytic Leukemia every 3 months. Thank you for your ongoing subscription to this publication.

Sincerely,
Elliot Jacob, Ph.D.
Vice-President - Content
Medifocus.com, Inc.



1:Venetoclax for the treatment of chronic lymphocytic leukemia.
Authors:Gentile M, Petrungaro A, Uccello G, Vigna E, Recchia AG, Caruso N, Bossio S, De Stefano L, Palummo A, Storino F, Martino M, Morabito F
Institution:a Hematology Unit, Department of Hemato-Oncology , Ospedale Annunziata , Cosenza , Italy. , Italy. , Italy. , Italy. Aprigliano , Italy. Aprigliano , Italy. Aprigliano , Italy. Aprigliano , Italy. Aprigliano , Italy. Aprigliano , Italy.
Journal:Expert Opin Investig Drugs. 2017 Nov;26(11):1307-1316. doi: 10.1080/13543784.2017.1386173. Epub 2017 Oct 9.

2:Novel synthetic drugs currently in clinical development for chronic lymphocytic leukemia.
Authors:Robak P, Robak T
Institution:a Department of Experimental Hematology , Medical University of Lodz , Lodz , Poland.
Journal:Expert Opin Investig Drugs. 2017 Nov;26(11):1249-1265. doi: 10.1080/13543784.2017.1384814. Epub 2017 Oct 3.

3:Liver dysfunction in chronic lymphocytic leukemia: Prevalence, outcomes, and pathological findings.
Authors:Hampel PJ, Chaffee KG, King RL, Simonetto D, Larson MC, Achenbach S, Call TG, Ding W, Kenderian SS, Leis JF, Chanan-Khan AA, Bowen DA, Conte MJ, Schwager SM, Hanson CA, Slager SL, Kay NE, Shanafelt TD, Parikh SA
Institution:Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota. Research, Mayo Clinic, Rochester, Minnesota. Mayo Clinic, Rochester, Minnesota. Rochester, Minnesota. Research, Mayo Clinic, Rochester, Minnesota. Research, Mayo Clinic, Rochester, Minnesota. Minnesota. Minnesota. Minnesota. Minnesota. Minnesota. Minnesota. Mayo Clinic, Rochester, Minnesota. Research, Mayo Clinic, Rochester, Minnesota. Minnesota. Minnesota. Minnesota.
Journal:Am J Hematol. 2017 Dec;92(12):1362-1369. doi: 10.1002/ajh.24915. Epub 2017 Oct 19.

4:Chronic lymphocytic leukemia with isochromosome 17q: An aggressive subgroup associated with TP53 mutations and complex karyotypes.
Authors:Collado R, Puiggros A, Lopez-Guerrero JA, Calasanz MJ, Larrayoz MJ, Ivars D, Garcia-Casado Z, Abella E, Orero MT, Talavera E, Oliveira AC, Hernandez-Rivas JM, Hernandez-Sanchez M, Luno E, Valiente A, Grau J, Portal I, Gardella S, Salgado AC, Gimenez MT, Ardanaz MT, Campeny A, Hernandez JJ, Alvarez S, Espinet B, Carbonell F
Institution:Servicio de Hematologia, Consorcio Hospital General Universitario, Valencia, Spain. Electronic address: collado_ros@gva.es.; Laboratori de Citogenetica Molecular, Servei de Patologia, Hospital del Mar, Barcelona, Spain; Grup de Recerca Translacional en Neoplasies Hematologiques, Cancer Research Program, IMIM-Hospital del Mar, Barcelona, Spain.; Laboratorio de Biologia Molecular, Fundacion Instituto Valenciano de Oncologia (FIVO), Valencia, Spain.; Servicio de Citogenetica, Departamento de Genetica, Universidad de Navarra, Pamplona, Spain.; Servei d'Hematologia, Hospital del Mar, Barcelona, Spain.
Journal:Cancer Lett. 2017 Nov 28;409:42-48. doi: 10.1016/j.canlet.2017.08.041. Epub 2017 Sep 6.

5:Combination therapy with the type II anti-CD20 antibody obinutuzumab.
Authors:Klein C, Bacac M, Umana P, Fingerle-Rowson G
Institution:a Roche Pharmaceutical Research & Early Development , Roche Innovation Center Zurich , Zurich , Switzerland. Zurich , Zurich , Switzerland. Zurich , Zurich , Switzerland. Switzerland.
Journal:Expert Opin Investig Drugs. 2017 Oct;26(10):1145-1162. doi: 10.1080/13543784.2017.1373087.

6:Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment.
Authors:Hallek M
Institution:Department I of Internal Medicine, Center for Integrated Oncology Koln Bonn, Center of Excellence on "Cellular Stress Responses in Aging-Associated Diseases," University of Cologne, Kerpener Strasse 62, Koln, 50937, Germany.
Journal:Am J Hematol. 2017 Sep;92(9):946-965. doi: 10.1002/ajh.24826.

7:New drug discovery approaches targeting recurrent mutations in chronic lymphocytic leukemia.
Authors:Tripathi R, Lee-Verges E, Higashi M, Gimenez N, Rosich L, Lopez-Guerra M, Colomer D
Institution:a Experimental Therapeutics in Lymphoid Malignancies Group, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Hematopathology Unit , Hospital Clinic, CIBERONC , Barcelona , Spain.
Journal:Expert Opin Drug Discov. 2017 Oct;12(10):1041-1052. doi: 10.1080/17460441.2017.1362387. Epub 2017 Aug 4.

8:Ibrutinib treatment improves T cell number and function in CLL patients.
Authors:Long M, Beckwith K, Do P, Mundy BL, Gordon A, Lehman AM, Maddocks KJ, Cheney C, Jones JA, Flynn JM, Andritsos LA, Awan F, Fraietta JA, June CH, Maus MV, Woyach JA, Caligiuri MA, Johnson AJ, Muthusamy N, Byrd JC
Institution:Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA.; The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA.; Biomedical Sciences Graduate Program, The Ohio State University.; Center for Biostatistics, The Ohio State University, Columbus, Ohio, USA.; Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Journal:J Clin Invest. 2017 Aug 1;127(8):3052-3064. doi: 10.1172/JCI89756. Epub 2017 Jul 17.

9:The safety of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia.
Authors:Tran PN, O'Brien S
Institution:a Division of Hematology-Oncology , University of California Irvine , Orange , CA , USA. , USA.
Journal:Expert Opin Drug Saf. 2017 Sep;16(9):1079-1088. doi: 10.1080/14740338.2017.1344213. Epub 2017 Jun 23.

10:IGHV mutational status testing in chronic lymphocytic leukemia.
Authors:Crombie J, Davids MS
Institution:Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. Massachusetts.
Journal:Am J Hematol. 2017 Dec;92(12):1393-1397. doi: 10.1002/ajh.24808. Epub 2017 Jul 29.

11:Safety and efficacy of Ofatumumab in chronic lymphocytic leukemia: a systematic review and meta-analysis.
Authors:Wu Y, Wang Y, Gu Y, Xia J, Kong X, Qian Q, Hong Y
Institution:a Medical Institution Conducting Clinical Trials for Human Used Drug, The Fifth People's Hospital of Shanghai , Fudan University , Shanghai , China.; b Department of General Psychiatry, Shanghai Mental Health Center , Shanghai Jiaotong University , Shanghai , China.; c Department of Hematology, The Fifth People's Hospital of Shanghai , Fudan University , Shanghai , China.; d Department of Osteology, The Fifth People's Hospital of Shanghai , Fudan University , Shanghai , China.
Journal:Hematology. 2017 Dec;22(10):578-584. doi: 10.1080/10245332.2017.1333974. Epub 2017 Jun 3.

12:Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.
Authors:Aw A, Brown JR
Institution:Division of Hematology, Department of Medicine, The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada. Harvard Medical School, 450 Brookline Avenue, Boston, MA, 02215, USA. Jennifer_Brown@dfci.harvard.edu.
Journal:Drugs Aging. 2017 Jul;34(7):509-527. doi: 10.1007/s40266-017-0468-4.

13:Pharmacotherapy of relapsed/refractory chronic lymphocytic leukemia.
Authors:Abou Zahr A, Bose P, Keating MJ
Institution:a Department of Leukemia , University of Texas MD Anderson Cancer Center , Houston , TX , USA. Houston , TX , USA. Houston , TX , USA.
Journal:Expert Opin Pharmacother. 2017 Jun;18(9):857-873. doi: 10.1080/14656566.2017.1324420. Epub 2017 May 16.

14:An update for Richter syndrome - new directions and developments.
Authors:Eyre TA, Schuh A
Institution:Department of Haematology, Cancer and Haematology Centre, Oxford University Hospitals NHS Trust, Oxford, UK. Trust, Churchill Hospital, Oxford, UK. Hospitals NHS Trust, Oxford, UK. Trust, Churchill Hospital, Oxford, UK. Foundation Trust, Oxford, UK.
Journal:Br J Haematol. 2017 Aug;178(4):508-520. doi: 10.1111/bjh.14700. Epub 2017 Apr 25.

15:Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL.
Authors:Ding W, LaPlant BR, Call TG, Parikh SA, Leis JF, He R, Shanafelt TD, Sinha S, Le-Rademacher J, Feldman AL, Habermann TM, Witzig TE, Wiseman GA, Lin Y, Asmus E, Nowakowski GS, Conte MJ, Bowen DA, Aitken CN, Van Dyke DL, Greipp PT, Liu X, Wu X, Zhang H, Secreto CR, Tian S, Braggio E, Wellik LE, Micallef I, Viswanatha DS, Yan H, Chanan-Khan AA, Kay NE, Dong H, Ansell SM
Institution:Division of Hematology and.
Journal:Blood. 2017 Jun 29;129(26):3419-3427. doi: 10.1182/blood-2017-02-765685. Epub 2017 Apr 19.

16:Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia.
Authors:Shustik C, Bence-Bruckler I, Delage R, Owen CJ, Toze CL, Coutre S
Institution:McGill University Health Centre, Montreal, Quebec, Canada. chaim.shustik@mcgill.ca. Canada. Calgary, AB, Canada. BC Cancer Agency and The University of British Columbia, Vancouver, BC, Canada. USA.
Journal:Ann Hematol. 2017 Jul;96(7):1185-1196. doi: 10.1007/s00277-017-2982-1. Epub 2017 Apr 7.

17:Duvelisib: a phosphoinositide-3 kinase delta/gamma inhibitor for chronic lymphocytic leukemia.
Authors:Vangapandu HV, Jain N, Gandhi V
Institution:a Department of Experimental Therapeutics , The University of Texas MD Anderson Cancer Center , Houston , TX , USA. Houston , TX , USA. Cancer Center , Houston , TX , USA.
Journal:Expert Opin Investig Drugs. 2017 May;26(5):625-632. doi: 10.1080/13543784.2017.1312338. Epub 2017 Apr 13.

18:Lenalidomide in the treatment of chronic lymphocytic leukemia.
Authors:Itchaki G, Brown JR
Institution:a Department of Medical Oncology , Dana Farber Cancer Institute , Boston , MA , USA. USA.
Journal:Expert Opin Investig Drugs. 2017 May;26(5):633-650. doi: 10.1080/13543784.2017.1313230. Epub 2017 Apr 17.

19:Targeted therapy in the treatment of chronic lymphocytic leukemia: facts, shortcomings and hopes for the future.
Authors:Molica S
Institution:a Department of Hematology-Oncology , Azienda Ospedaliera Pugliese-Ciaccio , Catanzaro , Italy.
Journal:Expert Rev Hematol. 2017 May;10(5):425-432. doi: 10.1080/17474086.2017.1313108. Epub 2017 Apr 12.

20:Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib.
Authors:Kaur V, Swami A
Institution:Department of Medicine, Division of Hematology/Oncology, University of Virginia, Charlottesville, VA, USA. varinderdhaliwal@gmail.com.
Journal:Ann Hematol. 2017 Jul;96(7):1175-1184. doi: 10.1007/s00277-017-2973-2. Epub 2017 Mar 24.

21:Factors predicting survival in chronic lymphocytic leukemia patients developing Richter syndrome transformation into Hodgkin lymphoma.
Authors:Mauro FR, Galieni P, Tedeschi A, Laurenti L, Del Poeta G, Reda G, Motta M, Gozzetti A, Murru R, Caputo MD, Campanelli M, Frustaci AM, Innocenti I, Raponi S, Guarini A, Morabito F, Foa R, Gentile M
Institution:Hematology, Department of Cellular Biotechnologies and Hematology, Sapienza University, Policlinico Umberto I, Rome. Mazzoni, Ascoli Piceno. Roma Tor Vergata, Rome. Policlinico, Milan. University, Policlinico Umberto I, Rome. University, Policlinico Umberto I, Rome. University, Policlinico Umberto I, Rome. University, Policlinico Umberto I, Rome. University, Policlinico Umberto I, Rome.
Journal:Am J Hematol. 2017 Jun;92(6):529-535. doi: 10.1002/ajh.24714. Epub 2017 Apr 18.

22:Prognosis biomarkers evaluation in chronic lymphocytic leukemia.
Authors:Gomes LC, Evangelista FCG, Sousa LP, Araujo SSDS, Carvalho MDG, Sabino AP
Institution:Clinical and Toxicological Analysis Department, Faculty of Pharmacy, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil. Electronic address: adriansabin@farmacia.ufmg.br.; Hematology Unit of Clinical Hospital, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil.
Journal:Hematol Oncol Stem Cell Ther. 2017 Jun;10(2):57-62. doi: 10.1016/j.hemonc.2016.12.004. Epub 2017 Feb 1.

23:A multicenter, single-arm, Phase II clinical trial of bendamustine monotherapy in patients with chronic lymphocytic leukemia in Japan.
Authors:Ogawa Y, Izutsu K, Kiguchi T, Choi I, Takatsuka Y, Ando K, Suzumiya J
Institution:Department of Hematology and Oncology, Tokai University Hospital, 143 Shimokasuya, Isehara, Kanagawa, 259-1193, Japan. yoshioga@is.icc.u-tokai.ac.jp. of Public School Teachers, Fukuyama, Japan. Fukuoka, Japan. Shimokasuya, Isehara, Kanagawa, 259-1193, Japan. Japan.
Journal:Int J Hematol. 2017 May;105(5):631-637. doi: 10.1007/s12185-016-2178-9. Epub 2017 Feb 3.

24:Development of acute myeloid leukemia in patients with untreated chronic lymphocytic leukemia.
Authors:Ito S, Fujiwara SI, Mashima K, Umino K, Minakata D, Nakano H, Yamasaki R, Kawasaki Y, Sugimoto M, Ashizawa M, Yamamoto C, Hatano K, Okazuka K, Sato K, Oh I, Ohmine K, Suzuki T, Muroi K, Kanda Y
Institution:Division of Hematology, Department of Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke, Tochigi, 329-0498, Japan. ycanda-tky@umin.ac.jp.
Journal:Ann Hematol. 2017 May;96(5):719-724. doi: 10.1007/s00277-017-2933-x. Epub 2017 Feb 1.

25:Leukemia-cell proliferation and disease progression in patients with early stage chronic lymphocytic leukemia.
Authors:Murphy EJ, Neuberg DS, Rassenti LZ, Hayes G, Redd R, Emson C, Li K, Brown JR, Wierda WG, Turner S, Greaves AW, Zent CS, Byrd JC, McConnel C, Barrientos J, Kay N, Hellerstein MK, Chiorazzi N, Kipps TJ, Rai KR
Institution:Department of Medicine, University of California, San Francisco, CA, USA. Diego, CA, USA. Diego, CA, USA. Berkeley, CA, USA. Diego, CA, USA.
Journal:Leukemia. 2017 Jun;31(6):1348-1354. doi: 10.1038/leu.2017.34. Epub 2017 Jan 24.

26:Venetoclax: A First-in-Class Oral BCL-2 Inhibitor for the Management of Lymphoid Malignancies.
Authors:King AC, Peterson TJ, Horvat TZ, Rodriguez M, Tang LA
Institution:1 Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Journal:Ann Pharmacother. 2017 May;51(5):410-416. doi: 10.1177/1060028016685803. Epub 2017 Jan 6.

27:Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia.
Authors:Freise KJ, Jones AK, Eckert D, Mensing S, Wong SL, Humerickhouse RA, Awni WM, Salem AH
Institution:Abbvie Inc., 1 North Waukegan Road, North Chicago, IL, 60064, USA. kevin.freise@abbvie.com.
Journal:Clin Pharmacokinet. 2017 May;56(5):515-523. doi: 10.1007/s40262-016-0453-9.

For a FREE PREVIEW of the Medifocus Guidebook on Chronic Lymphocytic Leukemia click here

To purchase a copy of the COMPLETE Medifocus Guidebook on Chronic Lymphocytic Leukemia click here

To subscribe to additional FREE Medifocus Digest Alert on other disease/condition areas click here

  
Get the Medifocus Guidebook on Chronic Lymphocytic Leukemia...
at a Special 20% Discount


Medifocus Guidebook on Chronic Lymphocytic Leukemia

Updated: June 20, 2017
176 Pages

This one of a kind Guidebook offers:

  • Answers to your critical health questions including the latest treatments, clinical trials, and expert research.
     
  • High Quality, Professional level information you can trust and understand culled from the latest peer-reviewed journals.
     
  • Timely, up to date content with free guidebook updates for 1 year.
     
  • A unique resource to find leading experts, institutions, and support organizations including contact information and hyperlinks.
     
  • Over 130,000 Guidebooks Sold
     
  • 100% Risk Free Money Back Guarantee



ORDER THE GUIDEBOOK

The Medifocus Guidebook on Chronic Lymphocytic Leukemia is available in the following two convenient formats:

PRINTED GUIDEBOOK

Soft-cover book that is available for immediate shipping via either U.S. Priority Mail or International AirMail (outside the U.S.).

  • Regular List Price = $36.95
  • Less 20% Discount = - $7.40
  • Discounted Price = $29.55(excluding shipping & handling)

Order the Printed Guidebook

DIGITAL GUIDEBOOK

Available for immediate download as a PDF document.

  • Regular List Price = $27.95
  • Less 20% Discount = - $5.60
  • Discounted Price = $22.35

Order the Digital Guidebook



Order by Phone

Call Toll Free in the U.S.
1-800-965-3002

From Outside the U.S.
1-301-649-9300

You can also receive a 20% discount when you order your Guidebook by phone.

To receive your 20% discount, simply mention the Discount Coupon Code below to the customer service representative taking your order.

Discount Coupon Code for
Phone Orders

CL52739155

Coupon Expires: January 10, 2018



What Our Customers Are Saying...

"I was recently diagnosed with CLL and searched all over the Web for information. I found the MediFocus Guidebook on Chronic Lymphocytic Leukemia to be a very useful resource. The information about chemotherapy was most important to me as well as recent studies concerning general treatments for this condition. The most valuable information was contained in the extensive references listed which were easy to access with a simple 'mouse' click. You are welcome to use my name as a reference."
G.C.
Coedpoeth, United Kingdom



  
Medifocus Digest Alert is published monthly by Medifocus, Inc.
6810 Park Heights Avenue, Suite C5, Baltimore, MD 21215 USA
Copyright © 2013 Medifocus, Inc. All rights reserved.